Nepsone

Executive Summary

Nepsone is a preclinical-stage pharmaceutical company developing novel small molecule drugs for dermatological conditions, with a primary focus on psoriasis. Based in Reykjavik, Iceland, the company was founded in 2019 and operates on a foundational neuroimmunology theory that attributes the origin of psoriasis to an imbalance in the autonomic nervous system and neuropeptide activity, diverging from the conventional immune-centric paradigm. Its therapeutics aim to restore neuro-immunological balance, potentially offering a differentiated mechanism of action. As a private, preclinical company, Nepsone has not yet disclosed total funding or valuation, and its platform remains unvalidated in clinical trials. The key risks include the early stage of development, the unproven nature of its neuroimmunology approach, and the challenges of advancing into human studies. However, its unique scientific premise could address unmet needs in dermatology if successfully translated.

Upcoming Catalysts (preview)

• Q4 2026Completion of GLP Toxicology Studies70% success
• Q2 2027IND/CTA Filing for Lead Candidate40% success
• Q3 2026Series A Financing Round60% success